Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cardiovascular requirements for Victoza will be met post approval, management predicts.
You may also be interested in...
UnitedHealth’s PBM Director Scans The 2009 Pharmaceutical Horizon
Pharmacy benefit managers face challenges in preparing their health plans for new product launches in 2009, given the increasingly unpredictable competitive environment for pharmaceuticals. A "nervous" FDA, fewer patents expiring for brand name drugs, and high barriers to developing truly better drugs have led to systemic bottlenecks in the availability of new products, and none of these factors are going away anytime soon
UnitedHealth’s PBM Director Scans The 2009 Pharmaceutical Horizon
Pharmacy benefit managers face challenges in preparing their health plans for new product launches in 2009, given the increasingly unpredictable competitive environment for pharmaceuticals. A "nervous" FDA, fewer patents expiring for brand name drugs, and high barriers to developing truly better drugs have led to systemic bottlenecks in the availability of new products, and none of these factors are going away anytime soon
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.